ArticleBiological trace element research2026
Carvacrol Modulates Cadmium-Induced Behavioral, Biochemical, Histopathological, and Metabolomic Alterations in rats.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Cadmium (Cd) is a toxic heavy metal that causes multi-organ damage, including neurotoxicity. Carvacrol (CAR), a natural phenolic compound obtained from aromatic plants, is known for its protective properties. This study investigated the effects of CAR against Cd-induced toxicity through comprehensive behavioral assessments including the Open Field Test (OFT), Elevated Plus Maze (EPM), Barnes Maze, and Rotarod test, while plasma biochemical parameters, liver and kidney histopathology, and untargeted metabolomic profiles (plasma and brain) were also evaluated. Male Wistar albino rats were randomly divided into six groups and orally administered Cd (50 mg/kg) and/or CAR (20 or 40 mg/kg body weight) for 12 days. CAR alone increased locomotor activity, altered neuroprotective related metabolic pathways and did not cause weight loss. Cd exposure significantly increased body weight loss and anxiety-like behaviors while elevating cortisol, urea, AST, ALT levels and inducing significant histopathological damage in liver and kidney tissues (p < 0.05). Integrated plasma-brain metabolomic analyses revealed that Cd exposure disrupts multiple interconnected biological systems, including the antioxidant defence system, mitochondrial energy pathways, and cell membrane integrity. Although Cd-CAR co-administration partially reversed worsening of the anxiolytic-like behavior, locomotor activity, and renal tissue integrity, it failed to fully prevent Cd-induced toxicity and further aggravated weight loss, biochemical alterations (creatinine, AST, ALT), and metabolic disturbances (p < 0.05). In conclusion, co-administration of CAR with Cd provided only limited and heterogeneous protection that was insufficient to counteract Cd-induced multisystem toxicity. This current study presents a wide assessment to the systemic use of CAR against Cd according to results of behavioral, histopathological, biochemical, and metabolomic parameters.
Indexed as
Identifiers
42717167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.